Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 121, Issue 2, Pages 109-116
Publisher
Springer Science and Business Media LLC
Online
2019-06-11
DOI
10.1038/s41416-019-0481-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events
- (2018) Rhian M. Touyz et al. Journal of the American Society of Hypertension
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
- (2018) Stephen J H Dobbin et al. HEART
- Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer
- (2017) Amit M. Oza et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
- (2017) Krishnansu S Tewari et al. LANCET
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review
- (2017) Ahmed M. Al-Abd et al. Journal of Advanced Research
- Predictive Value of Cumulative Blood Pressure for All-Cause Mortality and Cardiovascular Events
- (2017) Yan Xiu Wang et al. Scientific Reports
- Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
- (2016) Tobias Engel Ayer Botrel et al. BMC CANCER
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer
- (2016) Aya Nakaya et al. Cancer Medicine
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy
- (2015) C. K. Domigan et al. JOURNAL OF CELL SCIENCE
- The expanding role of primary care in cancer control
- (2015) Greg Rubin et al. LANCET ONCOLOGY
- Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
- (2015) Sven Mahner et al. Frontiers in Oncology
- Using bevacizumab to treat metastatic cancer: UK consensus guidelines
- (2014) D Miles et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
- (2014) Heather Yvonne Small et al. CANADIAN JOURNAL OF CARDIOLOGY
- Diagnosis and Management of Hypertension in Advanced Renal Cell Carcinoma: Prospective Evaluation of an Algorithm in Patients Treated with Sunitinib
- (2014) A. Bamias et al. JOURNAL OF CHEMOTHERAPY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people
- (2014) Eleni Rapsomaniki et al. LANCET
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
- (2013) Steven E. Lipshultz et al. CIRCULATION
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
- (2012) Nilka de Jesus-Gonzalez et al. AMERICAN JOURNAL OF HYPERTENSION
- Management of hypertension in adults in primary care: NICE guideline
- (2012) Terry McCormack et al. BRITISH JOURNAL OF GENERAL PRACTICE
- Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies
- (2012) Patrizia Ferroni et al. Current Vascular Pharmacology
- Management of Antiangiogenic Therapy-Induced Hypertension
- (2012) Nilka de Jesus-Gonzalez et al. HYPERTENSION
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of hypertension and proteinuria during angiogenesis inhibition
- (2012) Stephanie Lankhorst et al. JOURNAL OF HYPERTENSION
- Hypertension induced by antiangiogenic therapy: clinical and pathophysiological aspects
- (2012) Anton H van den Meiracker et al. European Journal of Hospital Pharmacy-Science and Practice
- Bevacizumab-Induced Hypertension
- (2011) Kostas N. Syrigos et al. BIODRUGS
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
- (2011) Samar Masoumi Moghaddam et al. CANCER AND METASTASIS REVIEWS
- An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
- (2011) M. Sitki Copur et al. Clinical Colorectal Cancer
- Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
- (2011) Filippo Bellati et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
- (2010) Gang Niu et al. CURRENT DRUG TARGETS
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- Treatment of bevacizumab-induced hypertension by amlodipine
- (2010) Olivier Mir et al. INVESTIGATIONAL NEW DRUGS
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker
- (2010) Emily S. Robinson et al. SEMINARS IN NEPHROLOGY
- Understanding and managing the possible adverse effects associated with bevacizumab
- (2009) S. S. Shord et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Management of hypertension in angiogenesis inhibitor-treated patients
- (2009) H. Izzedine et al. ANNALS OF ONCOLOGY
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now